Biomarkers in hypertension and their relationship with myocardial target-organ damage

Area of Science:

• Cardiology
• Clinical Medicine
• Biomarker Research

Background:

• Essential hypertension is a prevalent condition linked to long-term end-organ damage, notably premature cardiovascular disease.
• Current clinical practices lack effective methods for identifying hypertension patients at high risk for future cardiovascular comorbidities.
• Early identification of high-risk patients is crucial for implementing aggressive blood pressure management and disease-modifying therapies to prevent cardiovascular disease onset.

Purpose of the Study:

• To review the role of cardiac biomarkers in predicting future cardiovascular disease in patients with essential hypertension.
• To highlight the potential of cardiac biomarkers for early prognostic evaluation in hypertensive individuals.
• To provide an overview of specific cardiac biomarkers relevant for risk stratification in hypertension.

Main Methods:

• Literature review of studies investigating cardiac biomarkers and cardiovascular outcomes in hypertensive patients.
• Analysis of current research on the predictive value of various cardiac biomarkers.
• Synthesis of evidence regarding the utility of cardiac biomarkers for risk assessment in essential hypertension.

Main Results:

• Cardiac biomarkers can become abnormal long before the clinical manifestation of cardiovascular disease in hypertensive patients.
• Specific cardiac biomarkers show promise in identifying individuals with essential hypertension who are at increased risk for future cardiovascular events.
• The prognostic evaluation of hypertensive patients may be significantly enhanced by incorporating cardiac biomarker measurements.

Conclusions:

• Cardiac biomarkers offer a valuable tool for the early prognostic evaluation of patients with essential hypertension.
• Utilizing cardiac biomarkers can facilitate timely and targeted interventions to mitigate cardiovascular risk in hypertensive populations.
• Further research into cardiac biomarkers is warranted to refine risk stratification and personalize treatment strategies for essential hypertension.